1.曾益新.肿瘤学.第2版.北京：人民卫生出版社，2004.

2.Rosenberg SA.癌症生物治疗－原理与实践.陈复兴等，译.北京：人民军医出版社，2005.

3.罗荣城.肿瘤生物治疗学.北京：人民卫生出版社，2006.

4.姜文奇.肿瘤生物治疗学.广州：广东科技出版社，2006.

5.夏建川.肿瘤生物治疗基础与临床应用.北京：科学出版社，2011.

6.Rosenberg SA.Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin－2.J Biol Response Mod，1984，3（5）：501－511.

7.Ishikawa E，Takano S，Ohno T，et al.Adoptive cell transfer therapy for malignant gliomas.Adv Exp Med Biol，2012，746：109－120.

8.李殿俊，刘旭，张春艳，等.以LAK/IL－2为主的肿瘤过继免疫在国内的应用.肿瘤，1997，17（5）：330－332.

9.熊绍银，孙渝清，顾志勤.LAK细胞的临床应用.人民军医，1996（2）：50－52.

10.Rosenberg SA，Lotze MT，Yang JC，et al.Prospective randomized trial of high－dose interleukin－2alone or in conjunction with lymphokine－activated killer cells for the treatment of patients with advanced cancer.J Natl Cancer Inst，1993，85（8）：622－632.

11.Yang B，Lu XC，Yu RL，et al.Repeated transfusions of autologous cytokine－induced killer cells for treatment of haematological malignancies in elderly patients：apilot clinical trial.Hematol Oncol，2012，30 （3）：115－122.

12.Zhang Y，Wang J，Wang Y，Lu XC，Fan H，Liu Y，Zhang Y，Feng KC，Zhang WY，Chen MX，Fu X，Han WD.Autologous CIK cell immunotherapy in patients with renal cell carcinoma after radical nephrectomy.Clin Dev Immunol，2013，2013：195691.

13.Zhong R，Han B，Zhong H.A prospective study of the efficacy of a combination of autologous dendritic cells，cytokine－induced killer cells，and chemotherapy in advanced non－small cell lung cancer patients.Tumour Biol，2014，35（2）：987－994.

14.Dong M，Liang D，Li Y，et al.Autologous Dendritic Cells Combined with Cytokine－induced Killer Cells Synergize Low－dose Chemotherapy in Elderly Patients with Acute Myeloid Leukaemia.J Int Med Res.2012，40（4）：1265－1274.

15.Linn YC，Yong HX，Niam M，et al.A phaseⅠ/Ⅱclinical trial of autologous cytokine－induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission.Cytotherapy，2012，14（7）：851－859.

16.Laport GG，Sheehan K，Baker J，et al.Adoptive immunotherapy with cytokine－induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.Biol Blood Marrow Transplant，2011，17（11）：1679－1687.

17.Hontscha C，BorckY，Zhou H，et al.Clinical trials on CIK cells：first report of the international registry on CIK cells（IRCC）.Cancer Res Clin Oncol，2011，137（2）：305－310.

18.Rosenberg SA，Spiess P，Lafreniere R.A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes.Science，1986，233（4770）：1318－1321.

19.Besser MJ，Shapira－Frommer R，Treves AJ，et al.Clinical responses in a phaseⅡstudy using adoptive transfer of short－term cultured tumor infiltration lymphocytes in metastatic melanoma patients.Cancer Res，2010，16（9）：2646－2655.

20.Azimi F，Scolyer RA，Rumcheva P，et al.Tumor－infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma.J Clin Oncol，2012，30（21）：2678－2683.

21.Nielsen JS，Sahota RA.Milne K，et al.CD20 ⁺tumor－infiltrating lymphocytes have an atypical CD27－memory phenotype and together with CD8 ⁺T cells promote favorable prognosis in ovarian cancer.Clin Cancer Res，2012，18（12）：3281－3292.

22.Calcinotto A，Filipazzi P，Grioni M，et al.Modulation of microenvironment acidity reverses anergy in human and murine tumor－infiltrating T lymphocytes.Cancer Res，2012，72（11）：2746－2756.

23.Joseph RW，Peddareddigari VR，Liu P，et al.Impact of clinical and pathologic features on tumor－infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T～cell therapy.Clin Cancer Res，2011，17（14）：4882－4891.

24.Rong Y，Qin X，Jin D，et al.A phase I pilot trial of MUC1－peptide－pulsed dendritic cells in the treatment of advanced pancreatic cancer.Clin Exp Med，2012，12（3）：173－180.

25.Prins RM，Soto H，Konkankit V，et al.Gene expression profile correlates with T－cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy.Clin Cancer Res，2011，17（6）：1603－1615.

26.Dudley ME，Wunderlich JR，Robbins PF，et al.Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.Science，2002，298（5594）：850－854.

27.Ridolfi L，Ridolfi R，Riccobon A，et al.Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin－2in patients with resected stageⅢandⅣmelanoma.J Immunother，2003，26（2）：156－162.

28.Kugler A，Stuhler G，Walden P，et al.Regression of human metastatic renal cell carcinoma after vaccination with tumor cell－dendritic cell hybrids.Nat Med，2000，6（3）：332－336.

29.Forst P，Caliliw R，elldegrun A，et al.Immunosensitization of resistant human tumor cells to cyctotoxicity by tumor infiltrating lymphocytes.Int J Oncol，2003，22（2）：431－437.

30.Sabado RL，Bhardwaj N.Directing dendritic cell immunotherapy towards successful cancer treatment. Immunotherapy，2010，2（1）：37－56.

31.Um SJ，Choi YJ，Shin HJ，et al.Phase I study of autologous dendritic cell tumor vaccine in patients with non－small cell lung cancer.Lung Cancer，2010，70（2）：188－194.

32.Runbo Zhong，Jiajun Teng，Baohui Han，et al.Dendritic cells combining with cytokine～induced killer cells synergize chemotherapy in patients with late－stage non－small cell lung cancer.Cancer Immunol Immunother，2011，60（10）：1497－1502.

33.Wehner R，Dietze K，Bachmann M，et al.The bidirectional crosstalk between human dendritic cells and natural killer cells.J Innate Immun，2011，3（3）：258－263.

34.Levy EM，Roberti MP，Mordoh J.Natural killer cells in human cancer：from biological functions to clinical applications.J Biomed Biotechnol，2011，2011：676198.

35.Tonn T，Schwabe D，Klingemann HG，Becker S，Esser R，Koehl U，Suttorp M，Seifried E，Ottmann OG，Bug G.Treatment of patients with advanced cancer with the natural killer cell line NK－92.Cytotherapy.2013Dec；15（12）：1563－70.

36.Abonour R，Williams DA，Einhorn L，et al.Efficient retrovirus－mediated transfer of the multidrug resistance 1gene into autologous human long－term repopulating hematopoietic stem cells.Nat Med，2000，6 （6）：624－626.

37.Cavazzana－Calvo M，Hacein－Bey S，de Saint Basile G，et al.Gene therapy of human severe combined immunodeficiency（SCID）－X1disease.Science，2000，288（5466）：627－629.

38.Wang QJ，Wang H，Pan K，et al.Comparative study on anti－tumor immune response of autologous cytokine－induced killer（CIK）cells，dendritic cells－CIK（DC－CIK），and semi－allogeneic DC－CIK.Chin J Cancer，2010，29（7）：641－648.

39.Li H，Wang C，Yu J，et al.Dendritic cell－activated cytokine－induced killer cells enhance the anti－tumor effect of chemotherapy on non－small cell lung cancer in patients after surgery.Cytotherapy，2009，11 （8）：1076－1083.

40.Marten A，Ziske C，Schottker B，et al.Interactions between dendritic cells and cytokine－induced killer cells lead to an activation of both populations.J Immunother，2001，24（6）：502－510.

41.Zhan HL，Gao X，Pu XY，et al.Arandomized controlled trial of postoperative tumor lysate－pulsed dendritic cells and cytokine－induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma.Chinese Medical Journal，2012，125（21）：3771－3777.

42.Eli Gilboa.The promise of cancer vaccines.Nature Reviews Cancer，2004，4（5）：401－411.

43.Kantoff PW，Higano CS，Shore ND，et al.Sipuleucel－T Immunotherapy for castration～Resistant Prostate Cancer.N Engl J Med，2010，363（5）：411－422.

44.Quoix E，Ramlau R，Westeel V，et al.Therapeutic vaccination with TG4010and first－line chemotherapy in advanced non－small－cell lung cancer：a controlled phase 2Btrial.Lancet Oncol，2011，12（12）：1125－1133.

45.Reinhardt C，Zdrojowy R，Szczylik C，et al.Results of a randomized phaseⅡstudy investigating multipeptide vaccination with IMA901in advanced renal cell carcinoma（RCC）.J Clin Oncol，2010，28 （15s）：4529.

46.Greten TF，Forner A，Korangy F，et al.A phaseⅡopen label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma.BMC Cancer，2010，10：209.

47.Simon RM，Steinberg SM，Hamilton M，et al.Clinical trial designs for the early clinical development of therapeutic cancer vaccines.J Clin Oncol，2001，19（6）：1848－1854.

48.Armstrong AC，Hawkins RE.Vaccines in oncology：Background and clinical potential.Br J Radiol，2001，74（887）911－1002.

49.Jochems C，Tucker JA，Tsang KY，Madan RA，Dahut WL，Liewehr DJ，Steinberg SM，Gulley JL，Schlom J.A combination trial of vaccine plus ipilimumab in metastatic castration－resistant prostate cancer patients：immune correlates.Cancer Immunol Immunother，2014，63（4）：407－418.

50.Lennerz V，Gross S，Gallerani E，Sessa C，Mach N，Boehm S，Hess D，von Boehmer L，Knuth A，Ochsenbein AF，Gnad－Vogt U，Zieschang J，Forssmann U，Woelfel T，Kaempgen E.Immunologic response to the survivin－derived multi－epitope vaccine EMD640744in patients with advanced solid tumors.Cancer Immunol Immunother，2014，63（4）：381－394.

51.Noguchi M，Moriya F，Suekane S，Ohnishi R，Matsueda S，Sasada T，Yamada A，Itoh K.A phase II trial of personalized peptide vaccination in castration－resistant prostate cancer patients：prolongation of prostate－specific antigen doubling time.BMC Cancer，2013，30；13：613.

52.Perroud MW Jr，Honma HN，Barbeiro AS，et al.Mature autologous dendritic cell vaccines in advanced non－small cell lung cancer：aphase I pilot study.J Exp Clin Cancer Res，2011，30（1）：65－73.

53.Sawada Y，Yoshikawa T，Nobuoka D，et al.Phase I trial of a glypican－3－derived peptide vaccine for advanced hepatocellular carcinoma：immunologic evidence and potential for improving overall survival.Clin Cancer Res，2012，18（13）：3686－3696.

54.Draube A，Klein－González N，Mattheus S，et al.Dendritic cell based tumor vaccination in prostate and renal cell cancer：a systematic review and meta－analysis.PLoS One，2011，6（4）：18801.

55.Kabaker K，Shell K，Kaufman HL.Vaccines for colorectal cancer and renal cell carcinoma.Cancer J，2011，17（5）：283－293.

56.Rice J，Ottensmeier CH，Stevenson FK.DNA vaccines：precision tools for activating effective immunity against cancer.Nature Reviews Cancer，2008，8（1）：108－120.

57.Kirkwood J.Cancer immunotherapy：the interferon－alpha experience.Seminars in Oncology，2002，29（3 Suppl 7）：18－26.

58.Schwartzentruber DJ，Lawson DH，Richards JM，et al.Gp100Peptide Vaccine and Interleukin－2in Patients with Advanced Melanoma.N Engl J Med，2011，364（22）：2119－2127.

59.Su PJ，Chen JS，Liaw CC，et al.Biochemotherapy with carmustine，cisplatin，dacarbazine，tamoxifen and low－dose interleukin－2for patients with metastatic malignant melanoma.Chang Gung Med J，2011，34 （5）：478－486.

60.Yang JC，Sherry RM，Steinberg SM，et al.Randomized study of high－dose and low－dose interleukin－2in patients with metastatic renal cancer.J Clin Oncol，2003，21（16）：3127－3132.

61.Veneri D，Tecchio C，De Matteis G，et al.Long－term persistence of molecular response after discontinuation of interferon－alpha in two patients with chronic myeloid leukaemia.Blood Transfus，2012，10（2）：233－234.

62.Bourquin C，Hotz C，Noerenberg D，et al.Systemic cancer therapy with a small molecule agonist of tolllike receptor 7can be improved by circumventing TLR tolerance.Cancer Res，2011，71（15）：5123－5133.

63.Groenewegen G，Walraven M，Vermaat J，et al.Targeting the Endothelin Axis with Atrasentan，in combination with IFN－alpha，in metastatic renal cell carcinoma.Br J Cancer，2012，106（2）：284－289.

64.Kirkwood JM，Bender C，Agarwala S，et al.Mechanisms and management of toxicities associated with high－dose interferon alfa－2b.J Clin Oncol，2002，20（17）：3703－3718.

65.Trask PC，Esper P，Riba M，Redman B.Psychiatric side effects of interferon therapy：Prevalence，proposed mechanisms，and future directions.J Clin Oncol，2000，18（11）：2316－2326.

66.Martinez M，Ono N，Planutiene M，et al.Granulocyte－macrophage stimulating factor（GM－CSF）increases circulating dendritic cells but does not abrogate suppression of adaptive cellular immunity in patients with metastatic colorectal cancer receiving chemotherapy.Cancer Cell Int，2012，12（1）：2.

67.Lammel V，Stoeckle C，Padberg B，et al.Hypereosinophilia driven by GM－CSF in large－cell carcinoma of the lung.Lung Cancer，2012，76（3）：493－495.

68.Lawson DH，Lee SJ，Arhini AA，et al.PhaseⅢcooperative group study of yeast－derived granulocyte macrophage colony－stimulating factor（GM－CSF）versus placebo as adjuvant treatment of patients with completely resected stageⅢ－Ⅳmelanoma.J Clin Oncol，2010，28（15）（supp l）：612－613.

69.Wei G，Ni W，Chiao JW，et al.A meta－analysis of CAG（cytarabine，aclarubicin，G－CSF）regimen for the treatment of 1029patients with acute myeloid leukemia and myelodysplastic syndrome.J Hematol Oncol，2011，4：46.

70.Voloshin T，Gingis－Velitski S，Bril R，et al.G－CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth：prevention by a CXCR4antagonist.Blood，2011，118 （12）：3426－3435.

71.Xiao Y，Chen Y，Wen J，et al.Thymosinβ4：A Potential Molecular Target for Tumor Therapy.Crit Rev Eukaryot Gene Expr，2012，22（2）：109－116.

72.Zhang Q，Tang D，Zhao H，et al.Immunological therapies can relieve aromatase inhibitor－related joint symptoms in breast cancer survivors.Am J Clin Oncol，2010，33（6）：557－560.

73.林洪生.中医药防治肿瘤.北京：北京大学医学出版社，2008.

74.韩锐.抗癌中草药研究进展.中国新药杂志，1993，2（5）：1－7.

75.周岱翰.中西医结合肿瘤学的研究成就与发展前景.中医药通报，2003，2（1）：42－47.

76.Peng Z.Current status of gendicine in China：recombinant human Ad－p53agent for treatment of cancers.Hum Gene Ther，2005，16（9）：1016－1027.

77.Pan JJ，Zhang SW，Chen CB，et al.Effect of recombinant adenovirus－p53combined with radiotherapy on long－term prognosis of advanced nasopharyngeal carcinoma.J Clin Oncol，2009，27（5）：799－804.

78.Frew SE，Sammut SM，Shore AF，et al.Chinese health biotech and the billion－patient market.Nature Biotechnology，2008，26（1）：37－53.

79.Garber K.China Approves World's First Oncolytic Virus Therapy for Cancer Treatment.JNCI J Natl Cancer Inst，2006，98（5）：298－300.

80.Ayllón BS，Campo TJ，Cano SJ，et al.Gene therapy in the management of oral cancer：Review of the literature，Med Oral Patol Oral Cir Bucal，2008，13（1）：E15－21.

81.Cohen MH，Williams GA，Sridhara R，et al.FDA drug approval summary：gefitinib（ZD1839）（Iressa）tablets.Oncologist，2003，8（4）：303－306.

82.Fukuoka M，Wu YL，Thongprasert S，et al.Biomarker analyses and final overall survival res～ults from aphaseⅢ，randomized，open－label，first－line study of gefitinib versus carboplatin/paclitaxel inclinically selected patients with advanced non－small－cell lung cancer in Asia（IPASS）.J Clin Oncol，2011，29（21）：2866－2874.

83.Han JY，Park K，Kim SW，et al.First－SIGNAL：first－line single－agent iressa vers－us gemcitabine and cisplatin trial in never－smokers with adenocarcinoma of the lung.J Clin Oncol，2012，30（10）：1122－1128.

84.Shepherd FA，Rodrigues Pereira J，Ciuleanu T，et al.Erlotinib in previously treated non－small－cell lung cancer.N Engl J Med，2005，353（2）：123－132.

85.Tsao MS，Sakurada A，Cutz JC，et al.Erlotinib in lung cancer－molecular and clinical predictors of outcome.N Engl J Med，2005，353（2）：133－144.

86.Rosell R，Carcereny E，Gervais R，et al.Erlotinib versus standard chemotherapy as first－line t－reatment for European patients with advanced EGFR mutation－positive non－small－cell lung cancer（EURTAC）：a multicentre，open－label，randomized phase 3trial.Lancet Oncol，2012，13（3）：239－246.

87.Kindler HL，Niedzwiecki D，Hollis D，et al.Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer：phaseⅢtrial of the Cancer and Leukemia Group B（CALGB 80303）.J Clin Oncol，2010，28（22）：3617－3622.

88.Demetri GD，von Mehren M，Blanke CD，et al.Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.N Engl J Med，2002，347（7）：472－480.

89.Druker BJ，Guilhot F，O'Brien SG，et al.Five－year follow－up of patients receiving imatinib for chronic myeloid leukemia.N Engl J Med，2006，355（23）：2408－2417.

90.Escudier B，Eisen T，Stadler WM，et al.Sorafenib in advanced clear－cell renal－cell carcinoma.N Engl J Med，2007，356（2）：125－134.

91.Llovet JM，Ricci S，Mazzaferro V，et al.Sorafenib in advanced hepatocellular carcinoma.N Engl J Med，2008，359（4）：378－390.

92.Paz－Ares LG，Biesma B，Heigener D.PhaseⅢ，Randomized，Double－Blind，Placebo－Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First－Line Treatment of Advanced，Nonsquamous Non－Small－Cell Lung Cancer.J Clin Oncol，2012，30（25）：3084－3092.

93.Geyer CE，Forster J，Lindquist D，et al.Lapatinib plus capecitabine for HER2－positive advanced breast cancer.N Engl J Med，2006，355（26）：2733－2743.

94.CrinòL.Kim D，Riely GJ，et al.Initial phaseⅡresults with crizotinib in advanced ALK－positive nonsmall cell lung cancer（NSCLC）：PROFILE 1005.［abstract］.J Clin Oncol，2011，29（suppl 15）：Abstract 7514.

95.Shaw AT，Yeap BY，Solomon BJ，et al.Impact of crizotinib on survival in patients with advanced，ALK－positive NSCLC compared with historical controls.J Clin Oncol，2011，29（Suppl 15）：Abstract 7507.

96.Hu－Lowe DD，Zou HY，Grazzini ML，et al.Nonclinical antiangiogenesis and antitumor activities of axitinib（AG－013736），an oral，potent，and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1，2，3.Clinical cancer research：an official journal of the American Association for Cancer Research，2008，14（22）：7272－7283.

97.Rini BI，Escudier B，Tomczak P，et al.Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma（AXIS）：a randomised phase 3trial.Lancet，2011，378（9807）：1931－1939.

98.Van der Graaf WT，Blay JY，Chawla SP，et al.Pazopanib for metastatic soft－tissue sarcoma（PALETTE）：a randomised，double－blind，placebo－controlled phase 3trial.Lancet，2012，379（9829）：1879－1886.

99.Sternberg CN，Davis ID，Mardiak J，et al.Pazopanib in locally advanced or metastatic renal cell carcinoma：results of a randomized phaseⅢtrial.Journal of Clinical Oncology，2010，28（6）：1061－1068.

100.Shi Y，Zhang L，Liu X，et al.Icotinib versus gefitinib in previously treated advanced non－small－cell lung cancer（ICOGEN）：a randomised，double－blind phase 3non－inferiority trial.The lancet oncology，2013，14（10）：953－961.

101.Demetri GD，Reichardt P，Kang Y－K，et al.Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib（GRID）：an international，multicentre，randomised，placebo－controlled，phase 3trial.The Lancet，2013，381（9863）：295－302.

102.Grothey A，Van Cutsem E，Sobrero A，et al.Regorafenib monotherapy for previously treated metastatic colorectal cancer（CORRECT）：an international，multicentre，randomised，placebo－controlled，phase 3 trial.Lancet，2013，381（9863）：303－312.

103.Sequist LV，Yang JC－H，Yamamoto N，et al.PhaseⅢstudy of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.Journal of Clinical Oncology，2013，31（27）：3327－3334.

104.Elisei R，Schlumberger MJ，Müller SP，et al.Cabozantinib in progressive medullary thyroid cancer. Journal of Clinical Oncology，2013，31（29）：3639－3646.

105.Hauschild A，Grob J－J，Demidov LV，et al.Dabrafenib in BRAF－mutated metastatic melanoma：a multicentre，open－label，phase 3randomised controlled trial.The Lancet，2012，380（9839）：358－365.

106.Flaherty KT，Infante JR，Daud A，et al.Combined BRAF and MEK inhibition in melanoma with BRAF V600mutations.New England Journal of Medicine，2012，367（18）：1694－1703.

107.Flaherty KT，Robert C，Hersey P，et al.Improved survival with MEK inhibition in BRAF－mutated melanoma.New England Journal of Medicine，2012，367（2）：107－114.

108.Shah NP，Kantarjian HM，Kim DW，et al.Intermittent target inhibition with dasatinib 100mg once daily preserves efficacy and improves tolerability in imatinib－resistant and－intolerant chronic－phase chronic myeloid leukemia.Journal of clinical oncology，2008，26（19）：3204－3212.

109.Marin D，Ibrahim AR，Lucas C，et al.Assessment of BCR－ABL1transcript levels at 3months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.Journal of clinical oncology：official journal of the American Society of Clinical Oncology，2012，30（3）：232－238.

110.Cortes JE，Kim DW，Kantarjian HM，et al.Bosutinib versus imatinib in newly diagnosed chronic－phase chronic myeloid leukemia：results from the BELA trial.Journal of clinical oncology：official journal of the American Society of Clinical Oncology，2012，30（28）：3486－3492.

111.Chapman PB，Hauschild A，Robert C，et al.Improved survival with vemurafenib in melanoma with BRAF V600Emutation.The New England journal of medicine，2011，364（26）：2507－2516.

112.Wells SA，Jr.，Robinson BG，Gagel RF，et al.Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer：a randomized，double－blind phaseⅢtrial.Journal of clinical oncology，2012，30（2）：134－141.

113.Wang ML，Rule S，Martin P，et al.Targeting BTK with ibrutinib in relapsed or refractory mantle－cell lymphoma.The New England journal of medicine，2013，369（6）：507－516.

114.Slamon DJ，Leyland－Jones B，Shak S，et al.Use of chemotherapy plus a monoclonal antibody against HER2for metastatic breast cancer that overexpresses HER2.N Engl J Med，2001，344（11）：783－792.

115.Ismael G，Hegg R，Muehlbauer S，et al.Subcutaneous versus intravenous administration of（neo）adjuvant trastuzumab in patients with HER2－positive，clinical stageⅠ－Ⅲbreast cancer（HannaH study）：a phase 3，open－label，multicentre，randomised trial.Lancet Oncol，2012，13（9）：869－878.

116.De Bono JS，Bellmunt J，Attard G，et al.Open－label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy－naive patients with hormone－refractory prostate cancer.J Clin Oncol，2007，25（3）：257－262.

117.Baselga J，Cortés J，Kim SB，et al.Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.N Engl J Med，2012，366（2）：109－119.

118.Karapetis CS，Khambata－Ford S，Jonker DJ，et al.K－ras mutations and benefit from cetuximab in advanced colorectal cancer.N Engl J Med，2008，359（17）：1757－1765.

119.Vermorken JB，Mesia R，Rivera F，et al.Platinum－based chemotherapy plus cetuximab in head and neck cancer.N Engl J Med，2008，359（11）：1116－1127.

120.Lynch TJ，Patel T，Dreisbach L，et al.Cetuximab and first－line taxane/carboplatin chemotherapy in advanced non－small－cell lung cancer：results of the randomized multicenter phaseⅢtrial BMS099.J Clin Oncol，2010，28（6）：911－917.

121.Pescovitz MD，Greenbaum CJ，Krause－Steinrauf H，et al.Rituximab，B－lymphocyte depletion，and preservation of beta－cell function.N Engl J Med，2009，361（22）：2143－2152.

122.Taylor RP，Lindorfer MA，Zent CS.Anti－CD20antibody therapy for B－cell lymphomas.N Engl J Med，2012，367（9）：876－877.

123.Kaminski MS，Tuck M，Estes J，et al.131I－tositumomab therapy as initial treatment for follicular lymphoma.N Engl J Med，2005，352（5）：441－449.

124.Rai KR，Freter CE，Mercier RJ，et al.Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.J Clin Oncol，2002，20（18）：3891－3897.

125.Wierda WG，Kipps TJ，Mayer J，et al.Ofatumumab as single－agent CD20immunotherapy in fludarabine－refractorychronic lymphocytic leukemia.J Clin Oncol，2010，28（10）：1749－1755.

126.Hurwitz H，Fehrenbacher L，Novotny W，et al.Bevacizumab plus irinotecan，fluorouracil，and leucovorin for metastatic colorectal cancer.N Engl J Med，2004，50（23）：2335－2342.

127.Tao X，Sood AK，Deavers MT，et al.Anti－angiogenesis therapy with bevacizumab for patients with ovariangranulosa cell tumors.Gynecol Oncol，2009，114（3）：431－436.

128.Escudier B，Pluzanska A，Koralewski P，et al.Bevacizumab plus interferon alfa－2afor treatment of metastatic renal cell carcinoma：a randomised，double－blind phaseⅢtrial.Lancet，2007，370（9605）：2103－2111.

129.Hodi FS，O'Day SJ，McDermott DF，et al.Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med，2010，363（8）：711－723.

130.Robert C，Thomas L，Bondarenko I，et al.Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.N Engl J Med，2011，364（26）：2517－2526.

131.Douillard JY，Oliner KS，Siena S，et al.Panitumumab－FOLFOX4treatment and RAS mutations in colorectal cancer.N Engl J Med，2013，369（11）：1023－1034.

132.Amado RG，Wolf M，Peeters M，et al.Wild－type KRASis required for panitumumab efficacy in patients with metastatic colorectal cancer.J Clin Oncol，2008，26：1626－1634.

133.Poole RM，Vaidya A.Ramucirumab：First Global Approval.Drugs，2014Jun 12.［Epub ahead of print］

134.Fuchs CS，Tomasek J，Yong CJ，et al.Ramucirumab monotherapy for previously treated advanced gastric or gastro－oesophageal junction adenocarcinoma（REGARD）：an international，randomised，multicentre，placebo－controlled，phase 3trial.Lancet，2014，383（9911）：31－39.

135.Wadhwa R1，Taketa T，Sudo K，et al.Ramucirumab：a novel antiangiogenic agent.Future Oncol，2013，9 （6）：789－795.

136.Smith MR，Egerdie B，Hernandez Toriz N，et al.Denosumab in men receiving androgen－deprivation therapy for prostate cancer.N Engl J Med，2009，361（8）：745－755.